Drug Price Trends for glyburide

Average Pharmacy Cost for glyburide

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
GLYBURIDE 1.25 MG TABLET	00093-9477-53	0.06895	EACH	2026-03-18
GLYBURIDE 1.25 MG TABLET	62135-0583-30	0.06895	EACH	2026-03-18
GLYBURIDE 1.25 MG TABLET	72241-0038-05	0.06895	EACH	2026-03-18
GLYBURIDE 1.25 MG TABLET	23155-0056-01	0.06895	EACH	2026-03-18
GLYBURIDE-METFORMIN 5-500 MG	65862-0082-05	0.19202	EACH	2026-03-18

Glyburide Market Analysis and Price Projections

Last updated: February 19, 2026

Glyburide, a second-generation sulfonylurea, is a widely used oral medication for managing type 2 diabetes. Its efficacy in lowering blood glucose levels by stimulating insulin secretion from pancreatic beta cells has solidified its position in the diabetes treatment landscape. This report analyzes the current market dynamics, patent landscape, and projected price trends for glyburide.

What is the Current Market Size and Growth Trajectory for Glyburide?

The global glyburide market is characterized by its established presence and the availability of multiple generic formulations. While precise market size figures are often proprietary, industry estimates suggest a mature market with steady demand. The market growth is primarily driven by the increasing prevalence of type 2 diabetes worldwide and the affordability of generic glyburide compared to newer antidiabetic agents.

• Prevalence of Type 2 Diabetes: The International Diabetes Federation (IDF) estimates that over 537 million adults were living with diabetes in 2021, a figure projected to rise to 643 million by 2030 and 783 million by 2045 [1]. This rising incidence directly fuels demand for effective and accessible glucose-lowering medications like glyburide.
• Generic Dominance: Glyburide has long been off-patent, leading to a highly competitive generic market. This competition exerts downward pressure on prices, making it a first-line or second-line treatment option for a significant portion of the diabetic population, particularly in low- and middle-income countries.
• Market Segmentation: The market can be segmented by formulation (tablets, oral suspension) and distribution channel (hospital pharmacies, retail pharmacies, online pharmacies). Tablets represent the dominant formulation due to ease of administration and cost-effectiveness.

While specific growth rates for glyburide are not as dynamic as those for novel biologics or newer oral antidiabetics, the market is expected to maintain a stable, albeit modest, growth rate, estimated to be between 2% and 4% annually, driven by the sheer volume of patients with type 2 diabetes.

What is the Patent Landscape for Glyburide?

Glyburide, originally patented by Hoechst AG, has been off-patent for decades. The original patents for the compound itself expired in the late 1990s and early 2000s. This lack of patent exclusivity for the active pharmaceutical ingredient (API) has opened the door for widespread generic manufacturing.

• No New API Patents: There are no active patents protecting the core glyburide molecule that would prevent generic entry.
• Formulation and Manufacturing Patents: While the API is off-patent, some companies may hold patents related to novel formulations, extended-release mechanisms, or specific manufacturing processes. However, these are typically incremental and do not grant broad market exclusivity for the drug itself. Such patents are unlikely to significantly impact the overall generic market for standard glyburide formulations.
• Regulatory Exclusivity: Periods of regulatory exclusivity, such as data exclusivity or market exclusivity, are tied to the initial drug approval and do not apply to generic versions once the primary patent protection has expired.

The absence of patent barriers for the API is a key factor contributing to the affordability and accessibility of glyburide.

How Do Manufacturing Costs and Supply Chain Dynamics Influence Glyburide Pricing?

The manufacturing costs for glyburide are relatively low due to the mature and well-established production processes. The primary cost drivers are raw material sourcing, synthesis, quality control, and packaging.

• Raw Material Sourcing: The key starting materials for glyburide synthesis are readily available and produced by multiple chemical manufacturers globally. This ensures competitive pricing for the API.
• Manufacturing Efficiency: Generic manufacturers have optimized their production lines for high-volume, cost-efficient output. Many manufacturing facilities are located in regions with lower labor and overhead costs, further reducing production expenses.
• Supply Chain: The glyburide supply chain is robust, with numerous manufacturers and distributors ensuring consistent availability. This competitive landscape helps to keep prices low. Supply chain disruptions, while possible for any pharmaceutical, are less likely to cause significant price spikes for glyburide due to the wide base of suppliers.
• Quality Control and Regulatory Compliance: Adherence to Good Manufacturing Practices (GMP) and stringent quality control measures are essential and add to the cost. However, these are standard across the industry for all pharmaceutical products.

The low manufacturing costs and a stable supply chain contribute to glyburide being one of the most affordable oral antidiabetic medications available.

What are the Key Competitive Forces in the Glyburide Market?

The glyburide market is highly competitive, driven by numerous generic manufacturers and a price-sensitive customer base.

• Generic Competition: The market is populated by dozens of generic drug manufacturers globally. This intense competition leads to price erosion and limits the ability of any single manufacturer to dictate pricing.
• Therapeutic Alternatives: Glyburide competes with a wide array of other antidiabetic medications, including other sulfonylureas (e.g., glipizide, glimepiride), biguanides (metformin), DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, and insulin.
  • Metformin: Metformin is often considered the first-line therapy for type 2 diabetes due to its efficacy and favorable safety profile, and it is also a low-cost generic option.
  • Newer Classes: While newer drug classes (DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 RAs) offer distinct benefits and are often preferred for specific patient profiles or as add-on therapies, their higher price points limit their use as initial or broad-market treatments, especially in cost-constrained healthcare systems.
• Healthcare Payer Policies: Pharmacy benefit managers (PBMs) and national health formularies often favor lower-cost generics. Glyburide typically occupies a preferred or tier-1 position on formularies due to its cost-effectiveness, further solidifying its market share.
• Physician Prescribing Habits: While newer agents are gaining traction, many physicians continue to prescribe glyburide based on established efficacy, patient tolerance, and cost.

The competitive landscape is a significant factor in maintaining low prices and accessible supply.

What are the Projected Price Trends for Glyburide?

Given the factors of patent expiry, high generic competition, low manufacturing costs, and the availability of numerous therapeutic alternatives, glyburide prices are expected to remain stable with a slight downward trend in the medium term.

• Current Price Range: The average wholesale price (AWP) for a 30-day supply of glyburide tablets (e.g., 5 mg) typically ranges from \$5 to \$20, depending on the manufacturer, dosage, and region. This is a significant reduction from the prices of branded drugs and even newer generic antidiabetics.
• Projected Price Movement:
  • Short-Term (1-3 years): Prices are expected to remain largely stable, with minor fluctuations driven by supply-demand dynamics and potential changes in raw material costs. Any price increases would likely be marginal and absorbed by payers.
  • Medium-Term (3-7 years): A slight downward trend in real terms is anticipated. This is due to ongoing efforts by generic manufacturers to further optimize production and achieve economies of scale. Increased competition from emerging generic players in certain markets could also contribute to price moderation.
  • Long-Term (7+ years): Prices are likely to remain low and stable, subject to inflationary pressures. Significant price drops are improbable unless there are major shifts in manufacturing technology or a sudden oversupply in the market. The price floor is largely determined by the cost of production and basic distribution.

Factors that could influence price trends:

• Increased Generic Manufacturing Capacity: Expansion of manufacturing capacity by existing or new players could lead to increased supply and potentially lower prices.
• Raw Material Cost Volatility: While currently stable, significant increases in the cost of key chemical precursors could exert upward pressure on prices.
• Regulatory Changes: Changes in regulatory requirements for API production or finished product manufacturing could increase compliance costs.
• Emergence of Novel, Low-Cost Alternatives: While unlikely to displace glyburide entirely in the near future, the introduction of other highly affordable oral antidiabetics could indirectly pressure glyburide prices by offering comparable efficacy at similar or lower cost points.
• Healthcare Policy Shifts: Changes in government pricing regulations or formulary management strategies could impact pricing.

Key Takeaways

Glyburide maintains a stable and accessible market position driven by its long-standing patent expiry and robust generic competition. Its affordability, coupled with the growing global prevalence of type 2 diabetes, ensures continued demand. While pricing is expected to remain low and potentially trend downwards slightly, significant price volatility is unlikely. The competitive landscape, dominated by generic manufacturers and a wide array of therapeutic alternatives, will continue to anchor prices at cost-effective levels.

Frequently Asked Questions

1. Is glyburide still a recommended first-line treatment for type 2 diabetes? Metformin is generally considered the first-line oral therapy for type 2 diabetes. Glyburide is typically used as a second-line or add-on therapy, or as a first-line option in specific populations where other agents are contraindicated or unaffordable.

2. What is the typical cost of a 30-day supply of generic glyburide? A 30-day supply of generic glyburide tablets typically costs between \$5 and \$20, varying by manufacturer, dosage, and geographic region.

3. Are there any new patents expected to impact the glyburide market? No, the core glyburide molecule is off-patent, and no significant new patents are expected to grant market exclusivity for the active pharmaceutical ingredient. Patents may exist for novel formulations, but these are unlikely to broadly affect the generic market.

4. How does glyburide compare in price to other oral antidiabetic medications? Glyburide is substantially less expensive than newer classes of oral antidiabetics such as DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists. It is comparable in price to other older generic sulfonylureas and metformin.

5. What factors are most likely to cause a significant price change for glyburide? A significant price increase would likely require a substantial and sustained disruption in the global supply of key raw materials or a widespread withdrawal of major manufacturers due to unforeseen regulatory or quality issues. Conversely, a substantial price decrease would necessitate a major technological advancement in manufacturing that dramatically lowers production costs, which is improbable for a mature drug.

Citations

[1] International Diabetes Federation. (2021). IDF Diabetes Atlas 10th Edition 2021. Retrieved from https://www.diabetesatlas.org/